CORVALLIS, Montana April 26, 2006--SpeciGen announced today the appointment of Lonnie Bookbinder, MBA, Ph.D., of Corvallis Montana, as Chief Executive Officer. Dr. Bookbinder is the first CEO of SpeciGen and brings over 35 years of bio-pharmaceutical industry and executive experience to SpeciGen, an early stage drug development company. Dr. Bookbinder commented “SpeciGen has the potential to be a market leader in the diagnostic and drug delivery segments of the bio-pharmaceutical industry. Drug delivery is a fast growing marketplace for a number of significant reasons, including improvements in the safety profile of approved drugs, improvements in drug efficacy and the demands of large pharma and biotech companies looking for innovation to supplant struggling development pipelines.” “SpeciGen uses patented, new and unique drug delivery vehicles to create and develop products for the diagnostic imaging and therapeutic marketplaces. I am very pleased to become the CEO of SpeciGen and help build the Company from its’ early beginning in the state of Montana, where we have applied for two grants to establish a manufacturing facility and accelerate research on product candidates,” he said.
